LAUSANNE, Switzerland -- (BUSINESS WIRE) --
Philip Morris International Inc. (PMI) (NYSE: PM) today announced the appointment of Jorge Insuasty to the position of Chief Life Sciences Officer, effective Jan. 15, 2021. Mr. Insuasty will report to the company’s CEO, André Calantzopoulos.
“Jorge’s wealth of experience across both the pharmaceutical and consumer healthcare industries makes him the ideal candidate to succeed John O’Mullane, who is retiring,” said Calantzopoulos. “Jorge is a transformational leader in science and medicine and excels in driving product portfolio development through to market success. Science and a consumer-focused product portfolio are the cornerstones of our ambition to replace cigarettes with products that are a better choice than continued smoking. Jorge’s impressive track record will help ensure we reach our goals and take full advantage of adjacent revenue-generating opportunities.”
Mr. Insuasty joins PMI from Sanofi S.A., where most recently he was the Global Franchise Head of Immunology, Oncology, and Neurology for Sanofi Genzyme. During his nine-year tenure at Sanofi he led the company’s product pipeline strategy, from candidate selection through the development and regulatory review processes, with a dozen novel drugs approved. He orchestrated significant transformational change within the R&D and commercial functions to substantially increase speed and efficiency, fostered external collaboration and innovation, and was highly engaged with the investor community. Overall, he played a pivotal role in the turnaround of Sanofi’s R&D efforts.
Prior to Sanofi, Mr. Insuasty spent eight years at Novartis International AG as Global Head of Development, Neuroscience, and Ophthalmology. Before that, he was VP, Research and Development, Consumer Medicines at Bristol Myers Squibb. Mr. Insuasty holds an MD in cardiology from the University of Paris.
“I am very excited to join PMI,” said Insuasty. “The company’s transformation, and smoke-free vision represent a tremendous public health opportunity and a business challenge, both of which I will be thrilled to contribute toward. And I also look forward to developing adjacent future growth drivers.”
This appointment follows the recent announcement that John O’Mullane, PMI’s current Chief Life Sciences Officer, will retire.
“We thank John for the enormous contributions he has made these last two years, driving innovation and rigor into our life sciences function, and we wish him well in his retirement,” added Calantzopoulos.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand.
Carestream Health将其医疗保健IT业务
Boehringer Ingelheim Launches
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
Spesolimab meets primary
Vifor Pharma and Angion
Rimini Street荣获多项客户销售与服务世界奖
Aeternals:新型NFT和互动技术相结合
DCAS开始接受2024年非经销商委员会会员申请
Mythical Games完成3700万美元C1轮融资
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Kymeta 宣布其下一代天线、终端和全球移动连接
IDEMIA和Resa Airport Data Syst
面对疫情和经济危机,亿康先达发布强劲的20
Sabre选择DXC Technology来助力改变未
苏爱康医药宣布在日本推出Darvias®
电池生产商Hithium将为储能系统开发商Perfect
Intelsat向史密森国家航空航天博物馆捐赠
在大地上书写责任与担当——渭南师范学院孙樵
全球投资者法律顾问ROSEN鼓励Athira Pharma
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商
Mavenir的虚拟无线接入网(vRAN)连续第二年在
广成明股份参加番禺区先进制造业强区座谈会
深圳三匹马出行科技与江铃集团新能源战略合作
森永乳业的益生菌长双歧杆菌BB536在其50周年庆